Navigation Links
Kosan's Hsp90 Inhibitor, Tanespimycin, Shows 55% Clinical Benefit in Patients With Trastuzumab-Refractory Metastatic Breast Cancer
Date:12/17/2007

including a large number of partial responses, in this patient population supports the development of Hsp90 inhibition in the treatment of HER2-positive metastatic breast cancer and underscores the therapeutic potential of tanespimycin in this indication. These data confirm and extend the activity seen in the Phase 1 trial, described in our recent publication in the Journal of Clinical Oncology, and we are pleased to see this drug candidate continuing to deliver clinical benefit and advancing in the clinic."

"The data in this Phase 2 trial continue to strengthen as we have added patients," said Robert G. Johnson, Jr., M.D., Ph.D., Kosan's President and Chief Executive Officer. "We believe that tanespimycin is highly active in patients with HER2-positive metastatic breast cancer who have progressed on trastuzumab, and that this drug candidate's overall profile is attractive. We intend to complete this Phase 2 trial and embark upon next steps to explore tanespimycin's therapeutic potential in breast cancer."

Phase 2 Tanespimycin Data

Tanespimycin is an Hsp90 inhibitor that has demonstrated the potential to disrupt the activity of multiple oncogenes and cell signaling pathways implicated in tumor growth, including HER2, a key pathway in breast cancer.

The objective of the Phase 2 trial is to determine the objective response rate by RECIST in patients with HER2-positive metastatic breast cancer. To be eligible for the trial, patients may have had either progressive disease within 3 months following last dose of adjuvant treatment with trastuzumab or have progressive disease following initial therapy for metastatic disease with trastuzumab (trastuzumab may have been administered with cytotoxic chemotherapy or as a single agent). All but one patient received trastuzumab in the metastatic setting (one patient received trastuzumab only in the adjuvant setting). Tanespimycin was administered at a dose of 450 mg/m2 foll
'/>"/>

SOURCE Kosan Biosciences Incorporated
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. NexGenix Pharmaceuticals Enters into Exclusive World-wide License to Develop Novel Hsp90 Inhibitors
2. New Oral MEK Inhibitor, RDEA119, Shows Favorable Anti-Tumor Properties
3. 3 strikes, youre out? Refiling of Amendment to Change Constitution to Criminalize Stem Cell Cures Shows Trouble with Anti-Cures Cause
4. New Study Shows Promise for Hydrogen Sulfide in Reducing Heart-Attack Damage, Ikaria Announces
5. International Survey Shows People Over Forty Ignore Risk of Blindness
6. Aidas Rh-Apo2L Clinical Testing Shows Preliminary Efficacy in Helping to Treat Lung Cancer, Stomach Cancer, Lymphoma, Pancreatic Cancer & Kidney Cancer
7. Celator(R) Pharmaceuticals Study Shows CPX-571 Maintains Synergistic Ratio of Irinotecan and Cisplatin to Improve Anti-tumor Activity
8. Video shows buckyballs form by shrink wrapping
9. National Survey Shows Most Women Are Not Satisfied With Their Progesterone Treatment
10. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
11. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... Utah (PRWEB) August 27, 2014 Varian ... will expand its current Salt Lake City manufacturing facility ... outside of Utah to ultimately create 1,000 new full ... years. , “Utah is home to hardworking people ... can be credited with Varian’s success in the manufacturing ...
(Date:8/27/2014)... , Aug. 27, 2014 Reportlinker.com ... is available in its catalogue: ... http://www.reportlinker.com/p02316661/Global-Biodegradable-Packaging-Materials-Market-2014-2018.html ... materials that are readily decomposed by the ... conventional non-degradable packaging in terms of raw ...
(Date:8/27/2014)... NEW YORK , Aug. 27, 2014 /PRNewswire/ ... report is available in its catalogue: ... http://www.reportlinker.com/p02316662/Global-Chelating-Agents-Market-2014-2018.html About Chelating Agent ... can form covalent bonds with metal ions, thereby ... effect that some metal-ions have on chemical processes, ...
(Date:8/27/2014)... (PRWEB) August 27, 2014 “We are ... technology vendors,” said Ven Thangaraj, CEO of Radiant Sage. ... that are taking the imaging corelab market to a ... corelabs and research organizations to efficiently and effectively manage ... the data to be analyzed and read by trained ...
Breaking Biology Technology:Varian Medical Systems Groundbreaking on Facility Expansion Triggers Influx of New Jobs to Salt Lake 2Varian Medical Systems Groundbreaking on Facility Expansion Triggers Influx of New Jobs to Salt Lake 3Global Biodegradable Packaging Materials Market 2014-2018 2Global Biodegradable Packaging Materials Market 2014-2018 3Global Biodegradable Packaging Materials Market 2014-2018 4Global Biodegradable Packaging Materials Market 2014-2018 5Global Biodegradable Packaging Materials Market 2014-2018 6Global Biodegradable Packaging Materials Market 2014-2018 7Global Chelating Agents Market 2014-2018 2Global Chelating Agents Market 2014-2018 3Global Chelating Agents Market 2014-2018 4Radiant Sage Named to CIOReview List of 100 Most Promising Technology Companies 2
... 13 Jennerex, Inc. (San Francisco, CA,and Ottawa, ... that Samantha Miller has been appointed to the ... Ms. Miller has over 15 ... has negotiated, executed and managed numerous,global partnerships, as ...
... pleased to announce the appointment of Barry Lee as ... his 24 years of pharmaceutical sales and,marketing experience to ... the company. , (Photo: ... "We are extremely pleased to welcome Mr. Lee to ...
... risk to,patient safety in an economic downturn, the National ... Safety Congress will directly address,this issue through an extensive ... new thinking and tools critical to keeping patients,safe. , ... , This highly acclaimed annual ...
Cached Biology Technology:Jennerex Appoints Samantha Miller as Vice President of Corporate Development 2Patient Safety in Challenging Economic Times is Focus of NPSF Annual Congress on May 20-22 2
(Date:8/28/2014)... German . ... the help of sophisticated assembly lines. Mobile assembly carriers, on ... of these assembly lines. In the case of a car ... arranged in a precise spatial and chronological sequence, resulting in ... The creation of such an assembly line at molecular level ...
(Date:8/28/2014)... (LMU) in Munich have assigned a number of ... arthropods. These animals lived in shallow marine habitats ... found in Jurassic strata. , Before they ... habitat and were fossilized some 435 million years ... the Silurian seas although they were not ...
(Date:8/27/2014)... mysteries of the human genome was unveiled today in ... detailed comparison yet of how the genomes of the ... research, appearing August 28 in in the journal ... three species, genomes is "read out," and how their ... results add billions of entries to a publicly available ...
Breaking Biology News(10 mins):Nanoscale assembly line 2Nanoscale assembly line 3Paleontology: Oldest representative of a weird arthropod group 2Encyclopedia of how genomes function gets much bigger 2Encyclopedia of how genomes function gets much bigger 3Encyclopedia of how genomes function gets much bigger 4
... of harmful mercury in plants and animals, a new study ... Aquarium has compared levels of the chemical in captive dolphins ... fed a controlled diet, while the wild mammals dined on ... The study found lower levels of mercury in the captive ...
... medical information, but the sight of a needle often causes ... a team of researchers in Israel, however, can reveal much ... simply by shining a light through the skin. This optical ... high-resolution images of blood coursing through our veins without the ...
... University of Singapore,s (NUS) Department of Biological Sciences and Mechanobiology ... that is undergoing preclinical trials as a potential drug ... growing into a tumour. This drug-led compound is named BPTES. ... has provided evidence showing how a drug-lead compound suppresses tumour ...
Cached Biology News:Mercury in dolphins: Study compares toxin levels in captive and wild sea mammals 2Mercury in dolphins: Study compares toxin levels in captive and wild sea mammals 3New microscope uses rainbow of light to image the flow of individual blood cells 2New microscope uses rainbow of light to image the flow of individual blood cells 3Novel discovery by NUS scientists paves the way for more effective treatment of cancers 2